Two selective IGF1R inhibitors, picropodophyllin (PPP) and NVP-ADW742, demonstrated significant healthspan benefits when administered orally to 13-month-old C57BL/6 mice. NVP-ADW742 extended healthspan by 93 days through a "squarer" survival curve, while both compounds preserved short-term memory, reduced blood pressure and pulse rate, improved glucose tolerance in males, and prevented age-related frailty markers in females including grey hair and grip strength decline. This research validates a compelling therapeutic target rooted in evolutionary biology. IGF-1 signaling exemplifies antagonistic pleiotropy—beneficial for growth and development in youth but potentially detrimental for longevity. By selectively inhibiting IGF1R in middle-aged mice, researchers demonstrated that this pathway can be pharmacologically modulated to favor healthspan over growth signals. However, significant safety concerns emerged. PPP caused gastrointestinal bleeding, while NVP-ADW742 showed potential cardiotoxicity and concerning brain accumulation. These findings represent important proof-of-concept work but highlight the critical challenge facing IGF-1 pathway interventions: achieving therapeutic benefits while avoiding the toxicity that has historically plagued IGF1R inhibitors in cancer research. The 93-day healthspan extension, while modest, suggests this approach merits further development with safer compounds.